04Nov 2023
Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death

Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death

This study, conducted as part of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial, aimed to analyze the impact of the first prostate-specific antigen (PSA) level on prostate cancer (PCa) detection and PCa-specific mortality (PCSM) in a population-based screening setting with repeat screenings every 2–4 years. The study included men aged 55–69 years who attended at least one screening visit during a 16-year follow-up. The findings suggest that baseline PSA levels can guide decisions on the repeat screening interval, with a baseline PSA of <1.0 ng/ml in men aged 55–69 years being a strong indicator to delay or stop further screening.

  • #urology

Like

Save

Share